MedTrace Logo

A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors

NCT06257680 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-07-31

No results posted yet for this study

Summary

This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.

Conditions

  • Advanced Solid Tumor

Interventions

BIOLOGICAL

ReT01 ACT

Patients were infused with ReT01 ACT injection after pretreatment, and subjects were closely observed for 24 hours after each infusion.

Sponsors & Collaborators

  • Aeonvital Biomedicine

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-08
Primary Completion
2025-02-18
Completion
2027-02-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06257680 on ClinicalTrials.gov